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Aims Mortality after cardiac resynchronization therapy (CRT) is difficult to predict. We sought to design and validate a
simple prognostic score for patients implanted with CRT, based on readily available clinical variables, including age,
gender, left ventricular ejection fraction (LVEF), New York Heart Association (NYHA) class, presence/absence of atrial
fibrillation, presence/absence of atrioventricular junction ablation, coronary heart disease, diabetes, and implantation
of a CRT device with defibrillation.
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Methods For predictive modelling, 5153 consecutive patients enrolled in 72 European centres (79% male; LVEF 25.9± 6.85%;
NYHA class III–IV 77.5%; QRS 158.4± 32.3ms) were randomly split into derivation (70%) and validation (30%)
samples. The primary endpoint was total mortality and the secondary endpoint was cardiovascular mortality. The
final predictive model fit was assessed by plotting observed vs. predicted survival.
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Results In the entire cohort, 1004 deaths occurred over a follow-up of 14 409 person years. Total mortality ranged from
3.1% to 28.2% at 2 years in the first and fifth quintile of the risk score, respectively. At 5 years, total mortality was
10.3%, 18.6%, 27.6%, 36.1%, and 58.8%, from the first to the fifth quintile. Compared with the lowest quintile (Q),
total mortality was significantly higher in the other four quintiles [Q2 hazard ratio (HR)=1.71; Q3 HR = 2.20; Q4
HR = 4.03; Q5 HR = 8.03; all P < 0.001). The final model, which was based on the entire cohort using the above
variables, showed a good discrimination (Harrell’s c = 0.70) and high explained variation (0.26). The mean predicted
survival fitted well with the observed survival for up to 6 years of follow-up.
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Conclusions The VALID-CRT risk score, which is based on routine, readily available clinical variables, reliably predicted the
long-term total and cardiovascular mortality in patients undergoing CRT. While this score cannot be used to predict
the benefit of CRT, it may be useful for predicting survival after CRT. This may have useful implications for follow-up.
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Introduction
Cardiac resynchronization therapy (CRT) is a standard therapy
for patients with systolic heart failure (HF) and a prolonged QRS
duration.1–3 Although the treatment effect of this therapy is
superior to many others, the recognition of a variable outcome
has prompted efforts in risk-stratifying patients on the basis of
pre-implant assessments. Mechanical dyssynchrony measured by
echocardiography initially held promise as a predictor of outcome
after CRT.4–6 However, these measures have not stood the test of
a multicentre trial such as PROSPECT,4 in which no echocardio-
graphic measure of mechanical dyssynchrony proved to be useful
in predicting the response to CRT. Other imaging variables, such
as scar burden7,8 and scar location8,9 on cardiovascular magnetic
resonance have also been shown to predict the outcome of CRT.
Importantly, however, such measures have not been validated in
multicentre studies.
An accepted prognostic model for predicting survival in HF
patients is the Seattle Heart Failure Model (SHFM).10 Although
it takes into account the eventual use of CRT or implantable
cardioverter defibrillator (ICD) therapy, it was not specifically
designed for patients with HF who have already undergone CRT
device implantation. This, together with the fact that it requires
quantification of 25 variables, makes it unreliable and impractica-
ble. In contrast, relatively simple risk stratification systems, such
as the Euroscore used in cardiothoracic surgery,11 may seem sim-
plistic in terms of the few variables used, have nevertheless been
adopted worldwide. Similarly, the field of CRT demands a simple
risk-stratification algorithm based on few variables that are rou-
tinely available. In this study, we hypothesized that the long-term
mortality following CRT device implantation can be predicted using
a simple algorithm based on readily available clinical variables. We
have externally validated the utility of a simple predictive model
based on ‘real-world’ patients undergoing CRT.
Methods
This was a prospective, multicentre, international, longitudinal, obser-
vational study including consecutive patients undergoing CRT in the
period from May 1999 to February 2012 in 72 European centres (from
Italy, Switzerland, France, Germany, and England). This collaboration
arose from another larger experience, which comprised 95 centres
in Europe.12 The centres involved in the present study were those
that had systematically collected the data considered in this study. In
order to fit a prediction model for time to total and cardiovascular
death, variables that have previously been found to predict mortality in
other studies were considered. These included age, gender, ICD back
up, atrial fibrillation, presence or absence of atrioventricular junction
ablation (AVJA) in the case of atrial fibrillation, ischaemic aetiology,
diabetes, New York Heart Association (NYHA) class, left ventricular
ejection fraction (LVEF), QRS duration and morphology, left ventricu-
lar (LV) lead position, and creatinine.1,2,13–18 Although data collection
was prospective, the present analysis was retrospective. Data collec-
tion and analysis were approved by the individual sites’ Institutional
Review Board or Clinical Ethics Committee. The study conformed to
the Declaration of Helsinki. All patients gave written, informed consent
for data collection and analysis. ..
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.. Patient population
Inclusion criteria were: systolic HF in NYHA class III or ambulatory
IV (or II in the case of a recent hospitalization because of HF), LVEF
≤35% and QRS ≥120ms, despite maximum tolerated pharmacological
therapy with angiotensin-converting enzyme inhibitors or angiotensin
receptor-blockers, beta-adrenergic blockers, diuretics, and spironolac-
tone for at least 2 months. A clinical diagnosis of HF was made on the
basis of documented evidence of systolic dysfunction on echocardio-
graphy. A diagnosis of ischaemic cardiomyopathy was made if systolic
dysfunction was associated with a history of myocardial infarction
and/or if there was angiographically significant coronary heart disease.
Exclusion criteria were: contraindications to cardiac pacing; myocar-
dial infarction or acute coronary syndrome within the previous 3
months; severe structural valvular heart disease; and the presence of
co-morbidities likely to curtail survival to 12 months or less.
Device therapy
Transvenous CRT-pacing (CRT-P) or CRT-defibrillation (CRT-D)
device implantation was undertaken using standard transvenous tech-
niques under local anaesthesia. A lateral or posterolateral LV site was
considered optimal for LV lead by most implanters. In patients with
sinus rhythm, the CRT device was programmed in atrial-synchronous
sequential pacing. Atrioventricular optimization was undertaken
within 24 h of device implantation and at 6 months, using Doppler
echocardiography and the iterative method.19 In patients with atrial
fibrillation, the minimum heart rate was set at ≥70 bpm and the
maximum rate was set at 70% of the theoretical maximum heart rate.
A rate-adaptive response was activated both in atrial fibrillation (AF)
patients with and without AVJA.
Endpoints
The primary endpoint was total mortality and the secondary endpoint
was cardiovascular mortality. Patients undergoing left ventricular assist
device implantation or urgent heart transplantation were classified as
cardiac deaths. Mortality data was collected through medical records,
and where appropriate, from interviews with patient’s carers.
Statistical analysis
Data were described as mean and standard deviation (SD) if contin-
uous and as counts and per cent in the case of categorical variables.
For model building, the cohort was randomly split into a testing and a
validating sample, encompassing 70% and 30% of patients, respectively.
In order to fit a prediction model for time to total and cardiovascular
death, the following baseline predictors were considered: age, gender,
ICD back-up, atrial fibrillation, presence or absence of AVJA in case
of atrial fibrillation, ischaemic aetiology, diabetes, NYHA, LVEF, QRS
duration and morphology, LV lead position, and creatinine. Pharma-
cological treatment was not considered, as the choice and dosage is
strictly based on clinical indication, which in turn is measured by the
other variables. In order to retain a sufficient number of subjects in
the analysis, we only considered variables with missing data below 25%.
The missing mechanism was considered at random. All variables were
considered as candidate predictors; those with P< 0.1 at the univari-
able analysis were included in the model. Creatinine and natriuretic
peptides were not included in the model because of missing data
(>25%). Flexible Royston–Parmar models20 were fitted to the testing
© 2015 The Authors
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Table 1 Characteristics of the study group
Derivation (N= 3629) Validation (N= 1524) All (N= 5153)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Variable n Mean SD n Mean SD n Mean SD
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age (years) 3629 66.27 10.15 1524 66.39 10.15 5153 66.31 10.15
QRS duration (ms) 3629 158.4 32.3 1524 157.7 32.4 5153 158.2 32.3
LVEF (%) 3629 25.87 6.85 1524 25.84 6.72 5153 25.86 6.81
% % %
Sinus rhythm 3007 82.86 1257 82.48 4264 82.75
AF+ drugs 387 10.66 163 10.7 550 10.67
AF+AVJA 235 6.48 104 6.82 339 6.58
CRT-D 2740 75.5 1159 76.05 3899 75.66
Male gender 2845 78.4 1192 78.22 4037 78.34
CAD 1618 44.59 679 44.55 2297 44.58
NYHA III–IV 2812 77.49 1182 77.56 3994 77.51
Diabetes 904 24.91 370 24.28 1274 24.72
LBBB 2438 89.0 1003 89.3 3441 89.1
LV lead L/PL 1888 84.2 773 83.3 2661 83.6
LVEF, left ventricular ejection fraction; AF, atrial fibrillation; AVJA, atrioventricular junction ablation; CAD, coronary artery disease; CRT-D, cardiac resynchronization
defibrillation; NYHA, New York Heart Association; LBBB, left bundle branch block; L/PL, lateral or posterolateral LV position.
sample and the Weibull model was chosen as the more appropriate,
based on the Akaike information criterion. Linearity was checked and
proven for all continuous variables. Furthermore, continuous variables
were centred on the mean to draw plots of predicted survival. This
model was fitted in the testing sample; discrimination was assessed on
both the testing and validating samples. To this end, we created four
prognostic groups for all patients using cutpoints at the 15th, 50th,
and 85th centiles of the prognostic index (the linear combination of
predictors and their coefficients). These centiles approximated well to
the Cox cut points,21 thus minimizing the loss of information when dis-
cretizing a normally distributed continuous variable into a given number
of groups. We then plotted Kaplan–Meier curves for the two sam-
ples to assess discrimination graphically. Finally, both samples were
combined and the model was fitted again to derive the algorithm for
computation of the predictor index. The final model fit was assessed by
plotting observed and mean survival. The model Royston’s explained
variation and model Harrell’s c for discrimination were also computed.
The predictor index was then categorized into quintiles of its distribu-
tion to obtain groups at increasing risks of death and the corresponding
survival curves were plotted to allow derivation of the probability of
survival at each time-point at a given the risk category.20–22 Stata 13.1
(StataCorp, College Station, TX, USA) was used for statistical analysis.
A two-sided P-value< 0.05 was considered statistically significant.
Results
The study included 5153 patients with a median follow up of 39
months (Table 1) [age 66.3± 10.5 years (mean± SD), 79% men,
77% in NYHA III–IV, mean QRS 158± 32ms, 88% with left bundle
branch block (LBBB), LVEF 25.9± 6.8%, 25% prevalence of diabetes,
17% atrial fibrillation, 84%% with a lateral or posterolateral LV
lead position, and 76% implanted with an ICD back up). Patients
implanted with CRT were on optimized drug therapy: 85% were
treated with angiotensin-converting enzyme (ACE)-inhibitors or
angiotensin receptor blockers, 80% with beta-blockers, 54% with .
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.. spironolactone, 92% loop diuretics, 37% amiodarone, and 24%
treated with digoxin. Drug therapy and baseline characteristics
were similar in the derivation and validation samples. Over 14 409
person years of follow-up there were 1004 deaths.
Model construction
First, a parametric Weibull model was fitted in the testing sam-
ple of 3629 patients. Kaplan–Meier curves, constructed from four
predefined risk groups of the prognostic index, showed a good dis-
crimination, with perfect separation of the curves for the derivation
sample, which was maintained with acceptable approximation to
the validation sample (Figure 1). Given the good discrimination of
the tentative model in both the derivation and validation samples,
data were collapsed and a final Weibull parametric model was con-
structed on the entire cohort of 5133 patients. As shown in Table 2,
the risk of cardiovascular death was highest with advancing age, a
lower LVEF, AF without AVJA, male gender, ischemic aetiology, a
higher NYHA class (III and IV), and no ICD back up. Importantly,
QRS morphology and duration as well as LV lead location emerged
as non-significant predictors on univariable analyses (P> 0.5) and
dropped from the model. An algorithm to compute the predictor
index was derived from the model and, based on the quintiles of
its distribution, five groups of increasing risks were defined (Table 3
and Figure 2). The cumulative probability of dying at 2 years and 5
years is also reported for each risk group, with an almost linear
increase in risk for the first four groups and a major increase for
the fifth group at both 2 years and 5 years.
Model validation
The model showed good discrimination (Harrell’s c= 0.70) and
high explained variation (EV= 0.26). In addition, the mean survival,
© 2015 The Authors
European Journal of Heart Failure © 2015 European Society of Cardiology
720 M Gasparini et al.
Figure 1 Overall survival based on the prognostic index (PI). (a) discrimination ability of the prognostic model built in the testing sample.
Kaplan–Meier curves correspond to four groups built from the prognostic index (linear combination of predictors and their coefficients) with
predefined cut-offs. (b) the same prognostic index has been computed over the validating sample and Kaplan–Meier curves have been plotted
similarly.
Table 2 Multivariable Weibull prognostic model for
death from any cause
Predictor* HR 95% CI P
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age, yrs 1.03 1.02–1.03 <0.001
LVEF (%) 0.96 0.95–0.97 <0.001
SR 1.00
AF+ drugs 1.90 1.60–2.26 <0.001
AF+AVJAb 0.86 0.69–1.08 0.195
CRT-D (yesb) 0.52 0.45–0.59 <0.001
Gender (male) 1.50 1.26–1.78 <0.001
CAD (yes) 1.37 1.20–1.57 0.015
NYHA (III–IV) 2.32 1.85–2.90 <0.001
Diabetes (yes) 1.19 1.00–1.41 0.049
HR, hazard ratio; CI, confidence interval; LVEF, left ventricular ejection fraction;
SR, sinus rythm; AF, atrial fibrillation; AVJA, atrioventricular junction ablation;
CRT-D, cardiac resynchronization defibrillation; CAD, coronary artery disease;
NYHA, New York Heart Association.
*Test for AF: p< 0.001; AF+AVJA vs. AF+ drugs: HR 0.45, 95% CI 0.35–0.59,
P< 0.001.
Model P-value <0.001; Royston explained variation 0.26, Harrell’s c= 0.70.
Abbreviations as in Table 1
as predicted by the model fitted well the observed survival, as
shown by the Kaplan–Meier curves (Figure 2). In the lowest risk
group, however, the predicted survival after 6 years of follow-up
tended to be better than the observed survival. A good fit was .
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. observed to all other groups over the entire follow-up period.
Finally, when plotting the mean survival according to deciles of the
prognostic index, a good separation of curves emerged throughout
the range of values and time, confirming the good predictive ability
of the model. The model is:
Valid CRT score PI= 0.028× age 66− 0.044×LVEF25+
0.646×AF1-0.154×AF2-0.656× ICD+0.405×GENDER+
0.317×CAD+0.844×NYHA34+0.167×diabetes
where:
age66= age− 66 years;
LVEF= LVEF− 25;
AF1= 1 if AF without AVJA is present, 0 otherwise (meaning
both sinus rhythm or AF+AVJA);
AF2=1 if AF with AVJA is present, 0 otherwise (meaning both
sinus rhythm or AF without AVJA);
ICD, CAD, NYHA III–IV, diabetes= 1 if present, 0 otherwise;
gender= 1 if male, 0 if female.
Renal function data were missing in a consistent part of the
cohort, consequently, this datum could not be included, per pro-
tocol, into the main model (figure 3). Nonetheless, we decided,
to perform a second predictive model in the subgroup of patients
presenting baseline creatinine values. Owing to the lower num-
ber of patients included in this second model, this subgroup was
divided in three tertiles. As reported in the Supplementary material
online (Figure S1 and Table S1), even when creatinine was included,
the predicted and the validated survival curves remained perfectly
© 2015 The Authors
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Table 3 Algorithm for calculating the prognostic index (PI) and classifying patients in the pertinent risk groups*
Quintiles of PI PI min PI max 2-year mortality, % (95% CI) 5-year mortality, % (95%CI) HR (95% CI) Model P
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Risk group 1 −1.841 0.061 3.1 (2.1–4.5) 10.3 (7.8–13.6) 1.00
Risk group 2 0.062 0.558 5.9 (4.5–7.7) 18.6 (15.2–22.7) 1.71 (1.26–2.33) 0.001
Risk group 3 0.559 0.937 10.9 (9.0–13.3) 27.6 (23.5–32.3) 2.20 (2.10–3.33) <0.001
Risk group 4 0.938 1.364 13.9 (11.7–16.4) 36.1 (31.6–41.2) 4.03 (3.06–5.32) <0.001
Risk group 5 1.365 3.157 28.2 (25.3–31.4) 58.8 (54.4–63.2) 8.03 (6.18–10.45) <0.001
CI, confidence interval; HR, hazard ratio.
The model is: Valid cardiac resynchronization therapy (CRT) score PI= 0.028× age66 – 0.044×LVEF25+ 0.646×AF1–0.154×AF2 – 0.656× ICD+ 0.405×
GENDER+ 0.317×CAD+ 0.844×NYHA34+ 0.167×diabetes
where: age66= age− 66 years; LVEF= left ventricular ejection fraction – 25; AF1=1 if atrial fibrillation (AF) without atrioventricular junction ablation (AVJA) is present; 0
otherwise (meaning both sinus rhythm or AF+AVJA); AF2=1 if AF with AVJA is present, 0 otherwise (meaning both sinus rhythm or AF without AVJA); ICD, ; CAD, coronary
artery disease; New York Heart Association (NYHA) III–IV, diabetes=1 if present, 0 otherwise; gender=1 if male, 0 if female.
Figure 2 Observed and mean overall survival. Observed and
mean overall survival according to the quintiles of the predictor
index distribution; jagged lines correspond to the observed sur-
vival, while the dashed lines correspond to the mean survival as
computed from the parametric model.
superimposed, thus reinforcing the goodness of the predictive
model.
Discussion
In this study, we have shown that the VALID-CRT risk score, which
is based on a simple risk-stratification algorithm, reliably predicts
total and cardiovascular mortality after CRT. Importantly, the score
comprises nine variables that are readily available in clinical practice
and which have also been found to relate to a poor outcome in
other studies.1,2,13–18 On external validation, the predictive model
is reliable for up to 6 years of follow-up following CRT device
implantation. As we have no control group, this score should not be
employed to assess the survival benefit of CRT, but rather absolute
survival in patients after CRT device implantation. The score may
be of value in tailoring follow-up and treatment strategies in clinical
practice. In addition, this score may be useful in selecting patients
with specific risk profiles into clinical trials.
Several studies have shown that QRS duration before implanta-
tion relates to a survival benefit from CRT. A meta-analysis of indi-
vidual patient data frommajor CRT trials confirms a survival benefit .
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. at a QRS >140ms and less certain prognostic benefit between
120 and 140ms.23 In a post hoc analysis of REVERSE,24 there was
a linear relationship between clinical response and QRS durations,
starting at 120ms. In addition, QRS morphology also relates to sur-
vival benefit of CRT. A post hoc analyses of MADIT-CRT suggested
a reduced benefit in patients with non-LBBB QRS morphology.25
A meta-analysis of individual data from 3782 patients recruited
in landmark CRT trials, showed that while QRS duration was an
independent predictor of outcome after CRT, LBBB morphology
was not.23 This raises the possibility that the reduced benefit in
non-LBBB patients may relate to a shorter QRS duration rather
than to QRS morphology per se.
In this study, neither QRS duration nor morphology predicted
absolute survival after CRT. This, however, could be at least par-
tially due to the fact that almost 90% of patients had a QRS
>130ms and a LBBB. Echocardiographic measures of mechanical
dyssynchrony assessed before CRT device implantation have been
extensively studied as possible predictors of the response to and
outcome of CRT.26–30 In the multicentre PROSPECT study, how-
ever, no echocardiographic measure of mechanical dyssynchrony
proved to be useful in predicting response to CRT.4 Factors other
than measures of mechanical dyssynchrony have also been explored
as potential predictors. These include age, gender, NYHA class,
HF aetiology, atrial rhythm, QRS duration and morphology, LV
lead position, renal impairment, and biomarkers, such as natri-
uretic peptides13,26,27. As with echocardiography, studies on these
potential predictors of response to and survival benefit after CRT
have generally focused on one chosen factor without considera-
tion of other factors. Sample sizes have usually been small and
the follow-up period generally short (up to 6 months). More-
over, most studies have used surrogates of outcome, such as LV
reverse remodelling. Almost without exception, potential predic-
tors have not been externally validated by different centres in dif-
ferent countries. An algorithm based on pre-implant variables, such
as gender, heart failure aetiology, QRS complex morphology, LV
volume and left atrial volume was tested by Goldenberg et al.31 in
the MADIT-CRT study, but the follow-up was limited to 2.4 years.
A score consisting of a measure of dyssynchrony obtained from
cardiovascular magnetic resonance, location of myocardial scar and
creatinine has also been explored.32 However, this score involves
© 2015 The Authors
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Figure 3 Overall and cardiovascular mean survival and classification of patients into deciles of the predictive index (PI). In practical use, once
the PI has been computed for any given patients with the provided algorithm and classified in any of the 10 risk groups based on deciles, cardiac
(a) and overall (b) survival at any time can be read from the graph.
undertaking a cardiac magnetic resonance scan, which may not be
available in some centres. Moreover, the score has not been exter-
nally validated. The SHFM is a multifactorial model that predicts
mortality in patients with HF. The score has been validated in ran-
domized controlled trials and in community practice settings in
the USA and in Europe.10,33 The model has also been applied to
CRT trials, such as COMPANION1 and CARE-HF2 and takes into
account post-implant variables, such as device modality (CRT-P
or CRT-D). However, the follow-up in this validation is limited to
12 months and 29.4months, respectively. In a recent multicentre
external validation in patients undergoing CRT, the SHFM provided
only a modest predictive ability to predict survival.34 In contrast,
the VALID-CRT score, as presented herein, provides a good dis-
crimination between risk groups (c-statistic 0.70) in an external val-
idation of a large cohort of CRT patients with long-term follow-up.
Moreover, it involves entry of only nine readily available variables.
In our model, both AVJA (in patients with permanent AF) and the
use of CRT-D were associated with a favourable effect on survival,
which is in keeping with other studies.12,13 A further, important
limitation of the SHFM is its practicality, as it involves entry of 25
data fields. In contrast, the CRT risk score herein involves nine vari-
ables, which should be readily available to clinicians. In this respect,
it is similar to the Euroscore used in cardiac surgery.
Limitations
The aim of this study was to identify a simple, multi-factorial
algorithm that predicts mortality after CRT. While the dataset was ..
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. large, data collection cannot be compared with that of randomized
clinical trials. As is the case with long-term observational studies of
real-world practice, both indications to CRT and CRT technology
changed from 1999 to 2012. Admittedly, baseline renal function and
natriuretic peptides could add value to the predictive model, but
these were not included into the main model because of missing
data in more than 25% of cases. However we also reanalysed a
subgroup of patients presenting baseline renal function data; even
in this subgroup of patients both the predicted and the validated
survival curves remained perfectly superimposed, thus reinforcing
the goodness of the predictive model.
In addition, we have not considered changes in pharmacologi-
cal therapy throughout the follow-up period. Notwithstanding, our
model provided a reliable prediction of both total and cardiovas-
cular survival. An important distinction between the VALID-CRT
score and other scores31–34 is that it comprises variables that are
only available after implantation (e.g. device type). This is likely to
amount to a selection bias. As we have not assessed the score in
a control group not undergoing CRT, this score does not address
the relative benefits of CRT and, therefore, should not be used for
patient selection.
Conclusions
The VALID-CRT risk score is a simple, multifactorial
risk-stratification tool for patients implanted with CRT. Our
external validation involved prospective data collection in the
‘real-world’ clinical practice of 72 European centres. The score
© 2015 The Authors
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proved to be reliably predictive of both total and cardiovascular
mortality for up to 6 years of follow-up. In terms of clinical
application, this score should not be used in patient selection
but rather, for risk stratification following implantation of a
CRT device. Accordingly, patients with a high CRT risk score
might require more intensive follow-up or alternative and more
aggressive therapy than those with a low score. The model is
freely available online (http://www.validcrt.com) and in iPhone and
Android mobile phone applications.
Supplementary Information
Additional Supporting Information may be found in the online
version of this article:
FigureS1. Observed and mean overall survival in the second
model including the sub-group of patients with creatinine data.
TableS1.Observed and mean overall survival in the second model
including the sub-group of patients with creatinine data.
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